Closing Remarks on Unmet Needs in R/R FL

EP: 1.Follicular Lymphoma Background and Introduction to a Patient Case

EP: 2.First-, Second-, and Third-Line Treatment Selection for a FL Patient Case

EP: 3.Typical Treatment Responses in Patients with FL and Incidence of Relapsed or Refractory Disease

EP: 4.Considerations for Treatment Selection in the Third-Line R/R FL Setting

EP: 5.CAR T-cell Options for Patients with R/R FL

Now Viewing

EP: 6.Closing Remarks on Unmet Needs in R/R FL

EP: 7.Overview on Follicular Lymphoma and A Patient Case of Relapsed/Refractory Disease

EP: 8.Assessing Response to Therapy and High-Risk Disease in Follicular Lymphoma

EP: 9.Relapsed/Refractory Follicular Lymphoma: Sequencing Through Multiple Lines of Therapy

EP: 10.Novel Third-Line Therapies for Relapsed/Refractory Follicular Lymphoma

EP: 11.Practical Selection of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

EP: 12.Unmet Needs and Future Directions in Care for Relapsed/Refractory FL

Dr. Brian T. Hill: Despite the advances in follicular lymphoma, relapsed and refractory disease remains a problem. There are still many unmet needs. Probably the biggest one is for older frailer patients who are not candidates for intensive therapies such as CAR-T. There are newer agents that we've discussed that are active. But looking forward, there are combination trials that are ongoing that are exciting particularly as we look forward to the bispecific agents that target CD20 and our T cell engagers. This class of drug is in late stage clinical development and is very active in relapsed refractory follicular lymphoma patients. So I guess the advice I would have is if you're a provider, a general oncologist caring for patients with follicular lymphoma, and you have experience with chemoimmunotherapy and maybe some of the newer drugs, the field does advance quickly. And we have data just emerging in the past year or so about the safety and efficacy of CAR-T in relapsed refractory FL. So having conversations with your patients about referral and developing good relationships with specialists in your geographic area who can be available by cell phone or text to do some curbsiding to see if this is an appropriate way of thinking given all the evolving data in the field. So thank you to the audience. I hope you found this informative and look forward to speaking again in the future.